NCT05423691View on ClinicalTrials.gov

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

December 30, 2026

Conditions
Myelofibrosis
Interventions
DRUG

CK0804

CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.

Trial Locations (4)

10032

NOT_YET_RECRUITING

Columbia University, New York

10461

RECRUITING

Montefiore Einstein Cancer Center, The Bronx

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

95817

RECRUITING

UC Davis Health, Sacramento

Sponsors

Lead Sponsor

Cellenkos, Inc.
All Listed Sponsors
lead

Cellenkos, Inc.

INDUSTRY